Anti-GM-CSFRα or anti-GM-CSF showed significant clinical efficacy in RA patients without major adverse effects such as pulmonary alveolar proteinosis, which is caused by autoantibodies against GM-CSF (Behrens et al., 2015, Burmester et al., 2013). This evidence concerns the gene CSF2 and pulmonary alveolar proteinosis.